Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN versus DIPYRIDAMOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN versus DIPYRIDAMOLE.
Aspirin vs DIPYRIDAMOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) via acetylation, reducing prostaglandin and thromboxane A2 synthesis. Also activates lipoxin biosynthesis (inflammation resolution).
Inhibits platelet phosphodiesterase and blocks adenosine reuptake, increasing intracellular cAMP and adenosine levels, thereby inhibiting platelet aggregation; also causes coronary vasodilation.
325-650 mg PO q4-6h prn; max 4 g/day
Dipyridamole immediate-release tablets: 50-100 mg orally 3-4 times daily. Extended-release with aspirin: 200 mg orally twice daily.
None Documented
None Documented
30 minutes for aspirin (parent drug); salicylic acid: 2-3 hours after low doses, 15-30 hours after high doses due to saturable metabolism and renal reabsorption. Clinical context: prolonged half-life in overdose, renal impairment, and elderly patients.
Clinical Note
moderateDipyridamole + Tranilast
"Dipyridamole may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateDipyridamole + Resveratrol
"Dipyridamole may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateDipyridamole + Nimesulide
"Dipyridamole may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateDipyridamole + Hydrochlorothiazide
"The risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydrochlorothiazide."
Terminal elimination half-life is 10–12 hours in healthy adults; prolonged to 20–30 hours in hepatic impairment; clinical effect duration correlates with dosing interval.
Renal excretion of salicylates (75-85% as salicyluric acid, 10% as free salicylic acid, 5-10% as glucuronide conjugates); dose-dependent, with renal clearance decreasing at higher doses due to saturation of metabolic pathways. Biliary/fecal elimination is minimal (<5%).
Primarily hepatic metabolism (glucuronidation) with enterohepatic recirculation; biliary/fecal excretion accounts for >90% of eliminated drug; renal excretion of unchanged drug is negligible (<5%).
Category C
Category A/B
NSAID / Antiplatelet
Antiplatelet